Bruker (NASDAQ:BRKR) Announces Earnings Results

Bruker (NASDAQ:BRKR) posted its quarterly earnings results on Wednesday. The medical research company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08, FiscalAI reports. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $796.11 million. During the same period in the previous year, the firm posted $0.47 earnings per share. The business’s revenue was up 2.7% compared to the same quarter last year. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• Q1 results beat expectations with reported revenue of $823.4M (+2.7% reported, organic -4.4%) and non‑GAAP EPS of $0.31, and management reconfirmed full‑year guidance of $3.57B–$3.60B revenue and $2.10–$2.15 non‑GAAP EPS.
• Order momentum strengthened—BSI organic bookings grew in the high single digits and book‑to‑bill stayed >1 for the third consecutive quarter—management expects a return to organic revenue growth in Q2 (low‑ to mid‑single digits).
• Several idiosyncratic, AI‑driven growth engines are accelerating performance, including semi‑metrology (now >$300M annual), SciY lab‑digitization/software (~$50M), security detection (~$70M), and large multi‑year BEST superconductor orders, which management says provide durable secular tailwinds.
• Margins were pressured in Q1 (non‑GAAP gross margin 50%, operating margin 10.2%) by FX, tariffs and mix, but management expects a 250–300 bp non‑GAAP operating margin expansion in 2026 driven by cost‑savings (now tracking ~$140M annualized), though execution and macro risks remain.

Bruker Stock Up 11.2%

BRKR stock traded up $4.27 during midday trading on Wednesday, hitting $42.28. The company’s stock had a trading volume of 2,191,004 shares, compared to its average volume of 2,284,570. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The company has a market cap of $6.44 billion, a PE ratio of -281.89, a P/E/G ratio of 2.18 and a beta of 1.12. The firm’s 50-day moving average is $37.13 and its 200-day moving average is $41.99. Bruker has a 12 month low of $28.53 and a 12 month high of $56.22.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is -133.33%.

Key Headlines Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q1 beat — Bruker reported EPS of $0.31 versus the consensus ~$0.23 and revenue of $823.4M vs. ~$796.1M; revenue rose ~2.7% year‑over‑year, which supported the upside reaction. Zacks: Bruker Surpasses Q1 Earnings and Revenue Estimates
• Neutral Sentiment: FY‑2026 guidance essentially in line with expectations — management set EPS guidance of 2.10–2.15 and revenue guidance near $3.6B, which matches consensus and reduces uncertainty but doesn’t materially raise the bar. (See company press release/slide deck for details.) Bruker Press Release / Slide Deck
• Negative Sentiment: Profitability and YoY EPS compression — EPS declined from $0.47 a year ago to $0.31 this quarter and the company reported a slightly negative net margin (~‑0.25%), highlighting margin pressure that may limit upside absent margin improvement. MarketBeat: Q1 Results & Metrics
• Negative Sentiment: Investor sentiment noise — articles flagged insider selling and “earnings jitters,” which can amplify volatility even after a beat if investors worry about sustainability of improvement. Yahoo: Earnings Jitters and Insider Selling

Insider Activity

In other news, VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. This represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 27.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Large investors have recently modified their holdings of the business. Allworth Financial LP increased its position in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Bruker by 6.7% during the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock worth $284,000 after acquiring an additional 380 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in Bruker during the 4th quarter worth approximately $26,000. Finally, UMB Bank n.a. raised its stake in Bruker by 57.9% in the 4th quarter. UMB Bank n.a. now owns 1,571 shares of the medical research company’s stock valued at $74,000 after purchasing an additional 576 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Guggenheim cut their target price on Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Barclays lowered their target price on shares of Bruker from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Jefferies Financial Group set a $50.00 price objective on shares of Bruker in a research report on Thursday, February 12th. Citigroup reduced their target price on Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a research report on Friday, February 13th. Finally, UBS Group reissued a “neutral” rating and issued a $49.00 price target on shares of Bruker in a research note on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Bruker currently has an average rating of “Hold” and a consensus target price of $49.38.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.